UpFrontPSMA: 177Lu-PSMA-617 shows potential in mHSPC - Urology Times
177Lu-PSMA-617 plus docetaxel improved outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) without increased toxicity compared to docetaxel alone, according to the phase 2 UpFrontPSMA study. The addition of lutetium-PSMA to docetaxel significantly improved undetectable PSA levels at 48 weeks and multiple secondary endpoints with no increase in overall toxicity.
Related Clinical Trials
Reference News
Dr. Arun Azad discusses the UpFrontPSMA study, a Phase II trial comparing sequential lutetium-PSMA-617 and docetaxel versus docetaxel alone in metastatic hormone-sensitive prostate cancer (mHSPC). The study shows significant improvements in undetectable PSA at 48 weeks and multiple secondary endpoints with the addition of two cycles of lutetium-PSMA to docetaxel, highlighting its potential role in mHSPC treatment.
Sequential Lu-177–PSMA-617 and docetaxel achieved higher undetectable PSA rates vs docetaxel alone in high-volume metastatic hormone-sensitive prostate cancer patients, with no increased toxic effects.
177Lu-PSMA-617 plus docetaxel improved outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) without increased toxicity compared to docetaxel alone, according to the phase 2 UpFrontPSMA study. The addition of lutetium-PSMA to docetaxel significantly improved undetectable PSA levels at 48 weeks and multiple secondary endpoints with no increase in overall toxicity.
Dr. Arun Azad discusses the UpFrontPSMA study, a Phase II trial comparing sequential lutetium-PSMA-617 and docetaxel versus docetaxel alone in metastatic hormone-sensitive prostate cancer (mHSPC). The study shows significant improvements in undetectable PSA at 48 weeks and multiple secondary endpoints with the addition of two cycles of lutetium-PSMA to docetaxel, highlighting the potential for lutetium-PSMA to become part of a personalized mHSPC treatment approach.